Characteristics and trends of clinical trials on leukemia treatments: Analysis of the Peruvian Clinical Trial Registry (1995–2024)
Características y tendencias de los ensayos clínicos sobre tratamientos en leucemias: análisis del Registro Peruano de Ensayos Clínicos (1995-2024)
DOI:
https://doi.org/10.25176/RFMH.v2025i1.6825Keywords:
Ensayo Clínico Aleatorizado, Leucemia, Leucemia Mielógena Crónica BCR-ABL PositivaAbstract
Introduction: Clinical trials are essential in the fight against cancer, especially in the approach to Leukemias. The characteristics and trends of clinical trials on medical interventions are a relevant point to know due to the need for new treatments for the management of this disease. Objective: To describe the characteristics and trends of clinical trials on leukemia treatments reflected in REPEC. Methods: A descriptive study of the clinical trials of leukemias registered in the REPEC between 1995 and July 2024 was carried out. Data were collected on variables such as sponsor, phase of trial, type of leukaemia, design approach and type of outcome assessed. Results: Of the 2058 clinical trials located, 30 that met the inclusion criteria were included. The most studied type of leukemia was chronic, within this, myeloid had a higher percentage. Most of the studies were sponsored by the pharmaceutical industry, mostly foreign, and most were in phase 2 and 3. The most frequently evaluated outcome was progression-free survival, with most surrogate outcomes. Conclusions: The analysis of clinical trials on leukemias in REPEC reveals a high frequency and tendency to increase clinical studies on chronic leukemias.
Downloads
References
Sotelo-Rodríguez DC, Ruíz-Patiño A, Ricaurte L, Arrieta O, Zatarain-Barrón ZL, Cardona AF. Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies. Ecancermedicalscience. 2019;13:936. doi:10.3332/ecancer.2019.936
Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012;119(1):34–43. doi:10.1182/blood-2011-04-347872
32.pdf [Internet]. [citado el 15 de agosto de 2024]. Disponible en: https://www.dge.gob.pe/portal/docs/vigilancia/boletines/2014/32.pdf
Hernández-Martínez A, Roldán-Tabares MD, Herrera-Almanza L, Villegas-Alzate JD, Álvarez-Hernández LF, Hernández-Restrepo F, et al. Leucemia de manifestación aguda y las nuevas alternativas terapéuticas. Medicina interna de México. 2019;35(4):553–63. doi:10.24245/mim.v35i4.2548
González García S, Lavaut Sánchez K, González García S, Lavaut Sánchez K. Técnicas de citogenética para el estudio de las leucemias. Revista Cubana de Hematología, Inmunología y Hemoterapia [Internet]. 2022 [citado el 8 de agosto de 2024];38(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S0864-02892022000200002&lng=es&nrm=iso&tlng=pt
Mancero Rodríguez MJ, De la Paz Arellano Salinas K, Santo Cepeda KA, Esteban Rodríguez Revelo M. Leucemia linfoblástica aguda diagnostico. RECIMUNDO: Revista Científica de la Investigación y el Conocimiento. 2020;4(2):53–63.
Spreafico A, Hansen AR, Abdul Razak AR, Bedard PL, Siu LL. The Future of Clinical Trials Design in Oncology. Cancer Discov. 2021;11(4):822–37. doi:10.1158/2159-8290.CD-20-1301
Cahuina-Lope P, Solis-Sánchez G, Espíritu N. Características de los ensayos clínicos oncológicos presentados al Instituto Nacional de Salud del Perú, 1995-2019. Rev Peru Med Exp Salud Publica. 2021;37:739–45. doi:10.17843/rpmesp.2020.374.5167
SEER Cancer Statistics Review, 1975-2017 [Internet]. SEER. [citado el 5 de septiembre de 2024]. Disponible en: https://seer.cancer.gov/csr/1975_2017/index.html
Arzoun H, Srinivasan M, Thangaraj SR, Thomas SS, Mohammed L. The Progression of Chronic Myeloid Leukemia to Myeloid Sarcoma: A Systematic Review. Cureus. 14(1):e21077. doi:10.7759/cureus.21077
Desai RH, Zandvakili N, Bohlander SK. Dissecting the Genetic and Non-Genetic Heterogeneity of Acute Myeloid Leukemia Using Next-Generation Sequencing and In Vivo Models. Cancers (Basel). 2022;14(9):2182. doi:10.3390/cancers14092182
Cinco áreas terapéuticas centran el 63% de los ensayos clínicos en España [Internet]. [citado el 6 de septiembre de 2024]. Disponible en: https://www.saludyfarmacos.org/lang/es/boletin-farmacos/boletines/may202206/10_ci
Kim E, Yang J, Park S, Shin K. Factors Affecting Success of New Drug Clinical Trials. Ther Innov Regul Sci. 2023;1–14. doi:10.1007/s43441-023-00509-1
Gössling G, Rebelatto TF, Villarreal-Garza C, Ferrigno AS, Bretel D, Sala R, et al. Current Scenario of Clinical Cancer Research in Latin America and the Caribbean. Current Oncology. 2023;30(1):653–62. doi:10.3390/curroncol30010050
Tabares DH, Carrillo VP, Gómez JHD. Clasificación de los desenlaces en los ensayos clínicos. Medicina UPB. 2019;38(2):147–57.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista de la Facultad de Medicina Humana
This work is licensed under a Creative Commons Attribution 4.0 International License.
